2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow etirinotecan pegol: new trials by email Literature Review of etirinotecan pegol trials Research Report on etirinotecan pegol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine NKTR-102, Eribulin, Ixabepilone - Metastasis, Breast Cancer | Phase 3 | Completed | Nektar Therapeutics | 178 | 2016-11-01 | 2023-04-14 |
| The BEACON Study (Breast Cancer Outcomes With NKTR-102) NKTR-102, Treatment of Physician's Choice (TPC) - Locally Recurrent Breast Cancer, Metastatic Breast Cancer | Phase 3 | Completed | Nektar Therapeutics | 852 | 2011-12-01 | 2021-06-01 |
Breast Neoplasms (2) · Carcinoma (1) · Neoplasm Metastasis (1)
Belgium (2) · Canada (2) · France (2) · Italy (2) · Spain (2) · United Kingdom (2) · United States (2) · Australia (1) · Germany (1) · Israel (1) · Netherlands (1) · Portugal (1) · Russia (1) · South Korea (1)
PMID 26482278, PMID 28360015, PMID 28612225, PMID 30957581, PMID 31074641, PMID 35552364